| Literature DB >> 25505942 |
Rongjun He1, Yunpeng Bai1, Zhi-Hong Yu1, Li Wu1, Andrea Michelle Gunawan1, Zhong-Yin Zhang1.
Abstract
Mycobacterium protein tyrosine phosphatase B (mPTPB) is a potential drug target of Tuberculosis (TB). Small molecule inhibitors of mPTPB could be a treatment to overcome emerging TB drug resistance. Using a Diversity-Oriented Synthesis (DOS) strategy, we successfully developed a salicylic acid based and drug-like mPTPB inhibitor with an IC50 of 2 μM and >20-fold specificity over many human PTPs, making it an excellent lead molecule for anti-TB drug discovery. In addition, DOS generated bicyclic salicylic acids are also promising starting points for acquiring inhibitors targeting other PTPs.Entities:
Year: 2014 PMID: 25505942 PMCID: PMC4259018 DOI: 10.1039/C4MD00099D
Source DB: PubMed Journal: Medchemcomm ISSN: 2040-2503 Impact factor: 3.597